Birmingham Receives £10M to Build Advanced Biomanufacturing Facility for Cell and Gene Therapies
Key Insights
The University of Birmingham will receive £10M from the UK Government's Life Sciences Innovative Manufacturing Fund to develop three GMP-standard cleanrooms for advanced therapy manufacturing.
The facility will enable production of cell and gene therapies (search), mRNA vaccines (search), and medicines for clinical trials, addressing the West Midlands' lack of dedicated GMP manufacturing despite hosting over 50% of UK's advanced therapy trials.
The investment supports Birmingham's leadership in personalized medicine, including Europe's first trial of personalized mRNA vaccines (search) for pancreatic cancer (search).
The University of Birmingham has secured £10 million in government funding to establish a state-of-the-art biomanufacturing facility that will produce advanced cell and gene therapies (search), marking a significant step toward reducing the UK's reliance on overseas manufacturing for cutting-edge medical treatments.
The funding, announced by the UK Government's Department for Science, Innovation and Technology through the Life Sciences Innovative Manufacturing Fund (LSIMF), will support the development of three commercial cleanrooms at Good Manufacturing Practice (GMP) standard within the University's Precision Health Technologies Accelerator (search) (PHTA).
Addressing Critical Manufacturing Gap
The West Midlands currently hosts more than 50% of the UK's clinical trials for advanced therapies but lacks dedicated GMP manufacturing facilities. This gap has forced UK-funded companies to outsource advanced therapy production overseas, often preventing UK patients from participating in clinical trials involving these treatments.
"The UK, and particularly the West Midlands, urgently needs GMP cleanroom facilities to support the production of Advanced Therapy Medicinal Products and vaccines, including cell therapies and mRNA vaccines (search), as well as medicines for clinical trials," said Professor Gino Martini, Chief Executive Officer of PHTA.
Near-Patient Manufacturing Capabilities
The £10.7 million facility, located on the Birmingham Health Innovation Campus, will enable near-patient biomanufacturing of cell and gene therapies (search) and vaccines for both patient treatment and clinical trials. The cleanrooms will be positioned adjacent to Birmingham's clinical research facilities, including those at University Hospitals Birmingham NHS Foundation Trust.
Professor Neil Hanley, Birmingham Health Partners Executive Director and Head of the College of Medicine and Health at the University of Birmingham, emphasized the strategic importance of the location: "The value of this award is considerable, allowing us to create a comprehensive biomanufacturing capability in the middle of the country, directly adjacent to patients which we know is a priority for the Government and MHRA."
Supporting Groundbreaking Research
The facility will bolster Birmingham's existing leadership in advanced therapeutics, including Europe's first trial of a personalized mRNA vaccine for pancreatic cancer (search). This trial, conducted alongside University Hospitals Birmingham NHS Foundation Trust, tailors vaccines to each patient's tumor, training the immune system (search) to target and destroy remaining cancer cells after surgery to prevent recurrence.
The new cleanrooms will benefit from proximity to several world-leading research centers, including the NIHR Midlands-Wales Advanced Therapy Treatment Centre, the nationally-designated Cancer Research UK Clinical Trials Unit covering all childhood cancer (search) in the UK, and the UKRI-designated Centre of Excellence in Regulatory Science and Innovation in AI (CERSI).
Government Investment in Life Sciences
Science and Technology Secretary Liz Kendall highlighted the broader implications of the investment: "By manufacturing more medicines in this country we can make sure more people get the vital treatments they need. These investments will make a real difference to people across the country and show our Life Sciences Sector Plan is bearing fruit."
Dr Zubir Ahmed, Health Innovation and Safety Minister, added: "These investments mean more people living with conditions like bipolar disorder (search) will benefit from cutting-edge medicines - developed and manufactured right here in Britain."
Economic and Strategic Impact
The facility is expected to create highly skilled jobs and attract pharmaceutical and biotech companies to the West Midlands region. The investment will also strengthen the UK's pandemic preparedness capabilities and build resilience into the NHS by ensuring domestic manufacturing capacity for critical therapies.
"This new investment will allow us to achieve our point-of-care manufacturing ambitions, ensuring patients get access to the latest, most innovative medicines," Martini noted. "Having these facilities in place will also build resilience into the NHS, ensuring future pandemic preparedness."
The cleanroom laboratories will maintain controlled environments designed to minimize contamination by controlling airborne particles, temperature, humidity, and other environmental factors critical for pharmaceutical and biotechnology manufacturing where microscopic contaminants can compromise product quality and functionality.